Home

Insights

PE

Windlas Biotech Ltd P/E Ratio

Windlas Biotech Ltd P/E Ratio

download
stocks purchased

₹ 0.1 Cr

Volume transacted

stocks purchased

2.1 K

stocks traded

Last Updated time: 14 Jul 15:30 PM

Image

Windlas Biotech Ltd

NSE: WINDLAS

PE

25.2

Last updated : 14 Jul 15:30 PM

Key Highlights

    The P/E Ratio of Windlas Biotech Ltd is 25.2 as of 14 Jul 15:30 PM .a1#The P/E Ratio of Windlas Biotech Ltd changed from 12 on March 2019 to 11.1 on March 2023 . This represents a CAGR of -3.82% over 2 years. a1#The Latest Trading Price of Windlas Biotech Ltd is ₹ 700.55 as of 12 Jul 15:30 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.5 to 27.2 in 5 years. This represents a CAGR of -0.93%a1# The PE Ratio of Automobile industry is 17.2. The PE Ratio of Finance industry is 24.7. The PE Ratio of IT - Software industry is 29.2. The PE Ratio of Pharmaceuticals industry is 35.8. The PE Ratio of Retail industry is 143.1. The PE Ratio of Textiles industry is 12.1. In 2024a1#The Market Cap of Windlas Biotech Ltd changed from ₹ 457.9 crore on March 2019 to ₹ 479.02 crore on March 2023 . This represents a CAGR of 2.28% over 2 years. a1#The Revenue of Windlas Biotech Ltd changed from ₹ 122.79 crore to ₹ 175.73 crore over 8 quarters. This represents a CAGR of 19.63% a1#The EBITDA of Windlas Biotech Ltd changed from ₹ 16.65 crore to ₹ 26.45 crore over 8 quarters. This represents a CAGR of 26.04% a1#The Net Pr of Windlas Biotech Ltd changed from ₹ 9.8 crore to ₹ 16.99 crore over 8 quarters. This represents a CAGR of 31.67% a1#The Dividend Payout of Windlas Biotech Ltd changed from 19.79 % on March 2019 to 19.62 % on March 2023 . This represents a CAGR of -0.43% over 2 years. a1#

Open Demat Account

Lead form image

Enter your mobile no. to continue

+91

*By signing up you agree to our terms & conditions

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

×

Historical P/E Ratio of Windlas Biotech Ltd

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

Historical P/E Ratio of Windlas Biotech Ltd

Period
Mar '190
Mar '200
Mar '210
Mar '2212
Mar '2311.1

Company Fundamentals for Windlas Biotech Ltd

Market Cap

1,464 Cr

EPS

27.8

P/E Ratio (TTM) *

25.2

P/B Ratio (TTM) *

3.3

Day’s High

724.25

Day’s Low

698.0

DTE *

0.0

ROE *

12.9

52 Week High

792.45

52 Week Low

305.85

ROCE *

17.2

* All values are consolidated

Last Updated time: 14 Jul 15:30 PM

* All values are consolidated

Last Updated time: 14 Jul 15:30 PM

Image

Windlas Biotech Ltd

NSE: WINDLAS

PRICE

700.55

-11.70 (-1.64%)

stock direction

Last updated : 12 Jul 15:30

×

PRICE

The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.

Share price Over Time

1M

1Y

3Y

5Y

* All values are in Rupees

SWOT Analysis Of Windlas Biotech Ltd

Strength

5

S

Weakness

3

W

Opportunity

0

O

Threats

1

T

Asset Value vs Market Value of Windlas Biotech Ltd

Market Value

1,464

Asset Value

251

4.8 X

Value addition

* All values are in Rupees

Competitive Comparison of P/E Ratio

Company NamePEMarket Cap (INR Cr.)
Windlas Biotech Ltd251,464
Sun Pharmaceuticals Industries Ltd37378,675
Cipla Ltd28122,093
Divis Laboratories Ltd75120,480
Zydus Lifesciences Ltd30118,217
Dr Reddys Laboratories Ltd20112,137

Key Valuation Metric of Windlas Biotech Ltd

Earnings

58 Cr

25.2 X

PE Ratio

Market Cap

₹1464Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

Earnings

58 Cr

25.2 X

PE Ratio

Market Cap

₹1464Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

×

Historical Market Cap of Windlas Biotech Ltd

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Historical Market Cap of Windlas Biotech Ltd

Period
Mar '190
Mar '200
Mar '210
Mar '22458
Mar '23479

* All values are a in crore

×

Historical Revenue of Windlas Biotech Ltd

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Historical Revenue of Windlas Biotech Ltd

Period
Jun '22123
Sep '22135
Dec '22122
Mar '23143
Jun '23147
Sep '23156
Dec '23165
Mar '24176

* All values are a in crore

×

Historical EBITDA of Windlas Biotech Ltd

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

Historical EBITDA of Windlas Biotech Ltd

Period
Jun '2217
Sep '2219
Dec '2216
Mar '2319
Jun '2320
Sep '2322
Dec '2324
Mar '2426

* All values are a in crore

×

Historical Net Profit of Windlas Biotech Ltd

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Historical Net Profit of Windlas Biotech Ltd

Period
Jun '2210
Sep '2212
Dec '229
Mar '2311
Jun '2312
Sep '2314
Dec '2315
Mar '2417

* All values are a in crore

×

Historical Dividend Payout of Windlas Biotech Ltd

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Historical Dividend Payout of Windlas Biotech Ltd

Period
Mar '190
Mar '200
Mar '210
Mar '2220
Mar '2320

* All values are a in %

About Windlas Biotech Ltd

About Windlas Biotech Ltd

    Windlas Biotech Ltd (formerly known as Windlas Biotech Private Limited) was incorporated in the year 2001. The Company provides pharmaceutical development services, large-scale manufacturing services and authentic yet affordable products to its customers and consumers around the world. The company has state-of-the-art manufacturing plant facilities located in Dehradun, Uttarakhand, India. It also has a sales force and distribution network spread across 14 states. The company market its own manufactured authentic nutraceutical, pharmaceutical and Ayurvedic products to serve the semi-urban and rural communities at affordable prices. Apart from this, the company has three distinct strategic business verticals (SBVs) mainly comprising of CDMO services and products; domestic trade generics and over-the-counter (OTC) brands; and exports. The company provides a comprehensive range of CDMO services ranging from product discovery, product development, licensing and commercial manufacturing of generic products, including complex generics, in compliance with current Good Manufacturing Practices (GMP) with a focus on improved safety, efficacy and cost. In addition to this, it sells its own branded products in the trade generics and OTC markets as well as export generic products to several countries. Moreover, the company has significant experience in developing and manufacturing generic fixed dose combinations. Its focus has currently been in launching new complex generic products in the chronic therapeutic category linked to lifestyle related disorders. The company focused on developing and launching new complex generic products containing APIs which are difficult to handle or formulate. It needs pairing with a device to make a drug-device combo primarily in solid and liquid pharmaceutical dosage forms to provide specialized capabilities to customers especially for high potency, controlled substances and low-solubility products. Further, the development and manufacturing of complex generic products typically involves a higher degree of expertise/ trained manpower and utilizes higher overall process times. Its complex generic products portfolio primarily comprises fixed dosage combinations, fixed dosage plus modified release combinations, customized generics and chewable or dispersible. To conclude, the company has introduced high quality systems across its manufacturing facilities that cover the full product lifecycle from process innovation and R&D, through the stages of process development, manufacturing, sales, and supply chain, to the customer evaluation of products as well as management systems for ensuring consistent quality, efficacy, and safety of products. And hence forth, the company identifies and approves multiple vendors to source the raw materials pursuant to robust vendor assessment, in addition to the suppliers approved by its customers.

Windlas Biotech Ltd News Hub

News

Board of Windlas Biotech recommends final dividend

Windlas Biotech announced that the Board of Directors of the Company at its meeting held o...

Read more

20 May 202415:14

News

Windlas Biotech to announce Quarterly Result

Windlas Biotech will hold a meeting of the Board of Directors of the Company on 20 May 202...

Read more

11 May 202412:29

News

Windlas Biotech commissions its injectable facility

Windlas Biotech announced the commissioning of its state-of-the-art injectable facility fo...

Read more

02 Apr 202413:30

News

Windlas Biotech schedules board meeting

Windlas Biotech will hold a meeting of the Board of Directors of the Company on 8 February...

Read more

01 Feb 202412:42

News

Windlas Biotech to conduct board meeting

Windlas Biotech will hold a meeting of the Board of Directors of the Company on 8 November...

Read more

01 Nov 202316:25

News

Windlas Biotech to conduct AGM

Windlas Biotech announced that the 22th Annual General Meeting (AGM) of the company will b...

Read more

18 Aug 202316:15

Product Composition by Percentage (Revenue)

FAQs for PE of Windlas Biotech Ltd

What is Windlas Biotech Ltd current share price?

The current market price of Windlas Biotech Ltd as of July 14, 2024 is ₹700.55.

What is Windlas Biotech Ltd's market cap?

Windlas Biotech Ltd's market capitalisation stood at ₹1,464 Cr as of July 14, 2024

What are Windlas Biotech Ltd's total net assets?

According to Windlas Biotech Ltd's most recent financial filings, the company's net assets total ₹250.7 Cr.

Is Windlas Biotech Ltd making a profit or loss?

Windlas Biotech Ltd's net Profit as of July 14, 2024 is close to ₹58 Cr.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199